Efficacy and safety of bortezomib in patients with plasma cell leukemia (pages 2285–2290)
Pellegrino Musto, Fausto Rossini, Francesca Gay, Vincenzo Pitini, Tommasina Guglielmelli, Giovanni D'Arena, Felicetto Ferrara, Nunzio Filardi, Roberto Guariglia, Antonio Palumbo and for the GISMM, GISL, and GIMEMA Cooperative Groups, Italy
Version of Record online: 27 APR 2007 | DOI: 10.1002/cncr.22700
Bortezomib induced an overall response rate of 92% in 12 patients with plasma cell leukemia (PCL). The median progression-free survival was 8 months (range, 5 to >21 months) and toxicity was acceptable. Bortezomib, employed alone or in combination with other drugs, could contribute toward improving the usually poor prognosis of patients with PCL.